Single-use Technologies in Fill–Finish Operations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Single-use Technologies in Fill–Finish Operations
Single-use components in the fill–finish line provides increased flexibility to multiproduct manufacturers.


Pharmaceutical Technology
Volume 35, Issue 10, pp. 58-60

Time savings and flexibility

Perhaps the biggest benefit to be gained by implementing a single-use filling line is the savings in time gained by eliminating the cleaning and validation steps. Nathan Beyeler, process engineer at Merck Sharp and Dohme, cited the decrease in changeover time as being an important factor in the decision to implement a single-use fill line. "Market pressure and good business sense dictate that we need to use our filling assets for manufacturing product, not for getting ready to manufacture product," he says. "The need to get the most product out of the process is increasingly critical to the business. That said, the paradigm of a few blockbuster vaccines allowing for long campaign operation and few product-to-product changeovers is under pressure as products portfolios become more focused on multiple (lower annual volume) biologics. This means that a production facility is faced with the challenge of more frequently changing the facility and equipment over to process different products. The reduction of changeover time has therefore become one of the primary influences in our decision to implement single-use technology for current filling facilities."

Indeed, Beyeler reported a reduction in changeover time from 16 hours to two hours when switching to a single-use line. In addition, a recent report produced by authors from Millipore demonstrated a similar reduction in total processing time, from 19 hours to 1.5 hours, when switching from a stainless system to a single-use system (3).

On average, biotech companies outsource 81% of their fill-and-finish requirements. Biotech and pharmaceutical companies with in-house capabilities outsource 40% of their requirements (4). This means that CMOs are handling a large variety of filling operations, and can benefit from the flexibility afforded by single-use systems to handle multiple products. Althea's Duffy notes, "Stainless equipment requirements vary from client to client. When not in use, these must be stored and when they are placed back into service must be cleaned again." The ability to quickly reconfigure the line to accommodate different size runs, different biosafety requirements, or different product containers adds greater flexibility to the filling operation.

Evolving equipment requirements

It is often the case that equipment evolves to fill an unmet need, and this is the case with disposables for fill-finish. At its simplest, a filling line can consist of a product container bag, a pump and a filling needle, all connected by plastic tubing. Disposable filling lines, suitable for smaller-scale fills are available as "plug-and-play" systems, where the line comes fully assembled and presterilized, ready to be used. Such systems are adequate for small-scale fills, but do not operate at high speed and may not be suitable for high-viscosity products.

Pump technology has improved to the point where disposable filling lines are feasible, but further improvements are possible. Peristaltic pumps have only recently achieved the accuracy required for fill applications. They are still limited by speed, and the tubing that runs through the pump is subject to degradation and deformation over time. Plastic, disposable, rolling-diaphragm pumps are currently available and offer an alternative. However, more rigorous applications requiring high volume, high speed, or high pressure, may be places where stainless steel continues to be the better choice.

There is plenty of room for new technology to adapt to these challenges. Beyeler says, "At the moment, I think what has been offered is that which is the easiest and least risky to develop from the equipment vendors, a single-use version of what is already on the market. Some equipment suppliers for upstream processing have innovated beyond the 'also in single-use' type of approach and have developed specifically new technologies. As vendors increasingly see the potential competitive advantages for single-use technologies I am looking for them to specifically invest R&D in developing innovative filling technologies." The requirements for speed and cost-effectiveness in multiproduct manufacturing will drive the development of new disposable technologies for fill-finish operations.

References

1. Biotechnology Medicines in Development. PhRMA (September, 2011).

2. M. Hoffman, "Bioprocessing and Sterile Manufacturing" supplement to Pharm. Tech. 35, s6 (2011).

3. E. Jenness and V. Gupta, supplement to BioProcess Int. 9 (s2), 22–25 (2011).

4. J. Hartingan and W. Downey, GEN 31(10), (2011).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
21%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here